Correspondence: Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Sant Antoni Maria Claret, 167, 08025 Barcelona, Spain.
se ha leído el artículo
array:23 [ "pii" => "S1578219009700861" "issn" => "15782190" "doi" => "10.1016/S1578-2190(09)70086-1" "estado" => "S300" "fechaPublicacion" => "2009-06-01" "aid" => "70086" "copyright" => "Academia Española de Dermatología y Venereología and Elsevier España, S.L." "copyrightAnyo" => "2009" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2009;100:386-413" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2988 "formatos" => array:3 [ "EPUB" => 32 "HTML" => 1986 "PDF" => 970 ] ] "itemSiguiente" => array:18 [ "pii" => "S1578219009700873" "issn" => "15782190" "doi" => "10.1016/S1578-2190(09)70087-3" "estado" => "S300" "fechaPublicacion" => "2009-06-01" "aid" => "70087" "copyright" => "Academia Española de Dermatología y Venereología and Elsevier España, S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2009;100:414-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2806 "formatos" => array:3 [ "EPUB" => 39 "HTML" => 1430 "PDF" => 1337 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original articles</span>" "titulo" => "Multiple Primary Melanoma" "tienePdf" => "en" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "414" "paginaFinal" => "419" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Melanoma Primario Múltiple" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.R. Ferreres, A. Moreno, J. Marcoval" "autores" => array:3 [ 0 => array:2 [ "nombre" => "J.R." "apellidos" => "Ferreres" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Moreno" ] 2 => array:2 [ "nombre" => "J." "apellidos" => "Marcoval" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219009700873?idApp=UINPBA000044" "url" => "/15782190/0000010000000005/v1_201304241456/S1578219009700873/v1_201304241456/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S157821900970085X" "issn" => "15782190" "doi" => "10.1016/S1578-2190(09)70085-X" "estado" => "S300" "fechaPublicacion" => "2009-06-01" "aid" => "70085" "copyright" => "Academia Española de Dermatología y Venereología and Elsevier España, S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2009;100:374-85" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2949 "formatos" => array:3 [ "EPUB" => 37 "HTML" => 1810 "PDF" => 1102 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Novelties in dermatology</span>" "titulo" => "Electronic Medical History: Experience in a Dermatology Department" "tienePdf" => "en" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "374" "paginaFinal" => "385" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Historia Clínica en Soporte Electrónico: Experiencia de un Servicio de Dermatología" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.L. López-Estebaranz, V. Castilla-Castellano" "autores" => array:2 [ 0 => array:2 [ "nombre" => "J.L." "apellidos" => "López-Estebaranz" ] 1 => array:2 [ "nombre" => "V." "apellidos" => "Castilla-Castellano" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S157821900970085X?idApp=UINPBA000044" "url" => "/15782190/0000010000000005/v1_201304241456/S157821900970085X/v1_201304241456/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Consensus statement</span>" "titulo" => "Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "386" "paginaFinal" => "413" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "L. Puig, J.M. Carrascosa, E. Daudén, J.L. Sánchez-Carazo, C. Ferrándiz, M. Sánchez-Regaña, M. García-Bustinduy, X. Bordas, J.C. Moreno, J.M. Hernanz, S. Laguarda, V. García-Patos" "autores" => array:13 [ 0 => array:4 [ "nombre" => "L." "apellidos" => "Puig" "email" => array:1 [ 0 => "lpuig@santpau.cat" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff1" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor1" ] ] ] 1 => array:3 [ "nombre" => "J.M." "apellidos" => "Carrascosa" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff2" ] ] ] 2 => array:3 [ "nombre" => "E." "apellidos" => "Daudén" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff3" ] ] ] 3 => array:3 [ "nombre" => "J.L." "apellidos" => "Sánchez-Carazo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff4" ] ] ] 4 => array:3 [ "nombre" => "C." "apellidos" => "Ferrándiz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff2" ] ] ] 5 => array:3 [ "nombre" => "M." "apellidos" => "Sánchez-Regaña" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff5" ] ] ] 6 => array:3 [ "nombre" => "M." "apellidos" => "García-Bustinduy" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff6" ] ] ] 7 => array:3 [ "nombre" => "X." "apellidos" => "Bordas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "aff7" ] ] ] 8 => array:3 [ "nombre" => "J.C." "apellidos" => "Moreno" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">h</span>" "identificador" => "aff8" ] ] ] 9 => array:3 [ "nombre" => "J.M." "apellidos" => "Hernanz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">i</span>" "identificador" => "aff9" ] ] ] 10 => array:3 [ "nombre" => "S." "apellidos" => "Laguarda" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">j</span>" "identificador" => "aff10" ] ] ] 11 => array:3 [ "nombre" => "V." "apellidos" => "García-Patos" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">k</span>" "identificador" => "aff11" ] ] ] 12 => array:1 [ "colaborador" => "for the Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology" ] ] "afiliaciones" => array:11 [ 0 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona" "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff1" ] 1 => array:3 [ "entidad" => "Servicio de Dermatología. Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona" "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff2" ] 2 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital de la Princesa, Madrid" "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff3" ] 3 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital General de Valencia, Valencia" "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff4" ] 4 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Universitari Sagrat Cor, Barcelona" "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff5" ] 5 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Universitario de Canarias, Santa Cruz de Tenerife" "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff6" ] 6 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona" "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "aff7" ] 7 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Universitario Reina Sofía, Córdoba" "etiqueta" => "<span class="elsevierStyleSup">h</span>" "identificador" => "aff8" ] 8 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Infanta Leonor, Madrid" "etiqueta" => "<span class="elsevierStyleSup">i</span>" "identificador" => "aff9" ] 9 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Casa de Salud de Valencia, Valencia" "etiqueta" => "<span class="elsevierStyleSup">j</span>" "identificador" => "aff10" ] 10 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Universitari Vall d’Hebron, Barcelona, Spain" "etiqueta" => "<span class="elsevierStyleSup">k</span>" "identificador" => "aff11" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "⁎" "correspondencia" => "Correspondence: Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Sant Antoni Maria Claret, 167, 08025 Barcelona, Spain." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Directrices Españolas Basadas en la Evidencia Para el Tratamiento de la Psorias is Moderada a Grave Cona Gentes Biológicos" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Key words" "identificador" => "xpalclavsec84480" "palabras" => array:9 [ 0 => "psoriasis" 1 => "biologic agents" 2 => "guidelines" 3 => "treatment" 4 => "etanercept" 5 => "adalimumab" 6 => "infliximab" 7 => "efalizumab" 8 => "biologic therapy" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec84479" "palabras" => array:9 [ 0 => "psoriasis" 1 => "biológicos" 2 => "directrices" 3 => "tratamiento" 4 => "etanercept" 5 => "adalimumab" 6 => "infliximab" 7 => "efalizumab" 8 => "terapia biológica" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">Psoriasis vulgaris is an inflammatory skin disease that is generally chronic and that affects between 1% and 2% of the population in industrialized Western countries. It is associated with a marked decline in quality of life. A wide range of treatments are currently available, although surveys conducted before the advent of biologic agents reflected a strong degree of dissatisfaction with the treatments then available. Extensive scientific evidence has been gathered on the safety of biologic agents, and this has led to a review of the role of systemic treatment in general and has allowed new therapeutic goals and strategies to be contemplated in patients with moderate to severe psoriasis. In this new situation, there is a need for Spanish guidelines on the treatment of moderate to severe psoriasis with biologic agents, drafted by consensus among specialists and ratified by the Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology (AEDV). These guidelines should be evidence-based with regard to the pharmacologic characteristics, mechanism of action, administration route and regimen, efficacy, contraindications, adverse effects, and cost estimates of biologic agents approved for the treatment of moderate to severe psoriasis in Spain.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">La psoriasis vulgar es una enfermedad cutánea inflamatoria, de curso habitualmente crónico, que afecta a un 1-2% de la población en los países occidentales industrializados, y produce una reducción marcada de la calidad de vida de los pacientes. Pese a la diversidad de tratamientos disponibles, las encuestas efectuadas antes del advenimiento de los agentes biológicos demuestran un alto grado de insatisfacción con respecto a los tratamientos disponibles. Se ha acumulado abundante evidencia científica con respecto a la eficacia y seguridad de los agentes biológicos, que ha llevado a revisar el papel del tratamiento sistémico en general y ha permitido contemplar nuevos objetivos y estrategias terapéuticas en los pacientes con psoriasis moderada a grave. En este contexto nuevo se hace necesario establecer, de forma consensuada por especialistas expertos y ratificada por los integrantes del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología (AEDV), unas directrices para el tratamiento de la psoriasis moderada a grave con agentes biológicos, que incluyan información basada en la evidencia científica disponible acerca de las características farmacológicas, mecanismo de acción, vía y pautas de administración, eficacia, contraindicaciones, efectos adversos y estimaciones del coste de los agentes biológicos aprobados para el tratamiento de la psoriasis moderada a grave en España</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:120 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of psoriasis in Spain (Epiderma Project: phase I)" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2001" "volumen" => "15" "paginaInicial" => "20" "paginaFinal" => "23" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "La psoriasis, ¿una enfermedad sistémica?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2007" "volumen" => "98" "paginaInicial" => "396" "paginaFinal" => "402" "link" => array:1 [ …1] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis causes as much disability as other major medical diseases" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "1999" "volumen" => "41" "numero" => "3 Pt 1" "paginaInicial" => "401" "paginaFinal" => "407" "link" => array:1 [ …1] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriatic arthritis: epidemiology, clinical features, course, and outcome" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2004.032482" "Revista" => array:7 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2005" "volumen" => "64" "numero" => "Suppl 2" "paginaInicial" => "ii14" "paginaFinal" => "ii17" "link" => array:1 [ …1] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epidemiology of psoriatic arthritis in the population of the United States" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2005.03.046" "Revista" => array:5 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2005" "volumen" => "53" "paginaInicial" => "573" "link" => array:1 [ …1] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Eur J Dermatol" "fecha" => "2005" "volumen" => "15" "paginaInicial" => "279" "paginaFinal" => "283" "link" => array:1 [ …1] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/09546630600823369" "Revista" => array:6 [ "tituloSerie" => "J Dermatolog Treat" "fecha" => "2006" "volumen" => "17" "paginaInicial" => "279" "paginaFinal" => "287" "link" => array:1 [ …1] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "What characterizes the severity of psoriasis? Results from an epidemiological study of over 3,300 patients in the Iberian region" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000111511" "Revista" => array:7 [ "tituloSerie" => "Dermatology" "fecha" => "2008" "volumen" => "216" "paginaInicial" => "137" "paginaFinal" => "151" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The psoriasis area and severity index is the adequate criterion to define severity in chronic plaquetype psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000083509" "Revista" => array:6 [ "tituloSerie" => "Dermatology" "fecha" => "2005" "volumen" => "210" "paginaInicial" => "194" "paginaFinal" => "199" "link" => array:1 [ …1] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Current severe psoriasis and the Rule of Tens" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2005.06502.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2005" "volumen" => "152" "paginaInicial" => "861" "paginaFinal" => "867" "link" => array:1 [ …1] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on disease severity" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.143.2.239" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2007" "volumen" => "143" "paginaInicial" => "239" "paginaFinal" => "242" "link" => array:1 [ …1] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A systematic review of treatments for severe psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Health Technol Assess" "fecha" => "2000" "volumen" => "4" "paginaInicial" => "1" "paginaFinal" => "125" "link" => array:1 [ …1] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biological therapies in the systemic management of psoriasis: International Consensus Conference" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2004.06269.x" "Revista" => array:7 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2004" "volumen" => "151" "numero" => "Suppl 69" "paginaInicial" => "3" "paginaFinal" => "17" "link" => array:1 [ …1] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "German evidence-based guidelines for the treatment of psoriasis vulgaris (short version)" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00403-007-0744-y" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol Res" "fecha" => "2007" "volumen" => "299" "paginaInicial" => "111" "paginaFinal" => "138" "link" => array:1 [ …1] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2006.07405.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2006" "volumen" => "155" "paginaInicial" => "729" "paginaFinal" => "736" "link" => array:1 [ …1] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Members of the National Psoriasis Foundation: more extensive disease and better informed about treatment options" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.141.1.19" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2005" "volumen" => "141" "paginaInicial" => "19" "paginaFinal" => "26" "link" => array:1 [ …1] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Patients with psoriasis and their compliance with medication" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "1999" "volumen" => "41" "paginaInicial" => "581" "paginaFinal" => "583" "link" => array:1 [ …1] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10227-006-0103-1" "Revista" => array:7 [ "tituloSerie" => "J Cutan Med Surg" "fecha" => "2006" "volumen" => "9" "numero" => "Suppl 1" "paginaInicial" => "18" "paginaFinal" => "25" "link" => array:1 [ …1] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2005.06893.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2005" "volumen" => "153" "paginaInicial" => "486" "paginaFinal" => "497" "link" => array:1 [ …1] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2008.02.039" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2008" "volumen" => "58" "paginaInicial" => "826" "paginaFinal" => "850" "link" => array:1 [ …1] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1610-0387.2007.06172.x" "Revista" => array:7 [ "tituloSerie" => "J Dtsch Dermatol Ges" "fecha" => "2007" "volumen" => "5" "numero" => "Suppl 3" "paginaInicial" => "1" "paginaFinal" => "119" "link" => array:1 [ …1] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept and efalizumab for the treatment of psoriasis: a systematic review" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Health Technol Assess" "fecha" => "2006" "volumen" => "10" "paginaInicial" => "1" "paginaFinal" => "233" "link" => array:1 [ …1] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1185/030079908X291985" "Revista" => array:6 [ "tituloSerie" => "Curr Med Res Opin" "fecha" => "2008" "volumen" => "24" "paginaInicial" => "1237" "paginaFinal" => "1254" "link" => array:1 [ …1] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2008.08673.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2008" "volumen" => "159" "paginaInicial" => "274" "paginaFinal" => "285" "link" => array:1 [ …1] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2008.08732.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2008" "volumen" => "159" "paginaInicial" => "513" "paginaFinal" => "526" "link" => array:1 [ …1] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Puig L, Bordas X, Carrascosa JM, Daudén E, Ferrándiz C, Hernanz JM, et al. Documento de consenso sobre evaluación y tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Actas Dermosifiliogr. In press 2009." ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clindermatol.2007.10.027" "Revista" => array:6 [ "tituloSerie" => "Clin Dermatol" "fecha" => "2008" "volumen" => "26" "paginaInicial" => "509" "paginaFinal" => "514" "link" => array:1 [ …1] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Kragballe K, Bischof D, Papp K. 10 years of safety experience with efalizumab in psoriasis. Poster 3655, 21st World Congress of Dermatology, Buenos Aires, Argentina, September 30-October 5, 2007." ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A novel targeted T-cell modulator, efalizumab, for plaque psoriasis" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa030002" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2003" "volumen" => "349" "paginaInicial" => "2004" "paginaFinal" => "2013" "link" => array:1 [ …1] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jama.290.23.3073" "Revista" => array:6 [ "tituloSerie" => "JAMA" "fecha" => "2003" "volumen" => "290" "paginaInicial" => "3073" "paginaFinal" => "3080" "link" => array:1 [ …1] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib31" "etiqueta" => "31." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.141.1.31" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2005" "volumen" => "141" "paginaInicial" => "31" "paginaFinal" => "38" "link" => array:1 [ …1] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib32" "etiqueta" => "32." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2004.09.029" "Revista" => array:7 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2005" "volumen" => "52" "numero" => "3 Pt 1" "paginaInicial" => "425" "paginaFinal" => "433" "link" => array:1 [ …1] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib33" "etiqueta" => "33." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-4632.2006.02777.x" "Revista" => array:6 [ "tituloSerie" => "Int J Dermatol" "fecha" => "2006" "volumen" => "45" "paginaInicial" => "605" "paginaFinal" => "614" "link" => array:1 [ …1] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib34" "etiqueta" => "34." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2006.07344.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2006" "volumen" => "155" "paginaInicial" => "170" "paginaFinal" => "8127" "link" => array:1 [ …1] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib35" "etiqueta" => "35." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1610-0387.2006.06111.x" "Revista" => array:6 [ "tituloSerie" => "J Dtsch Dermatol Ges" "fecha" => "2006" "volumen" => "4" "paginaInicial" => "947" "paginaFinal" => "956" "link" => array:1 [ …1] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib36" "etiqueta" => "36." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Drugs Dermatol" "fecha" => "2004" "volumen" => "3" "paginaInicial" => "614" "paginaFinal" => "624" "link" => array:1 [ …1] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib37" "etiqueta" => "37." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2005.12.018" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2006" "volumen" => "54" "paginaInicial" => "S154" "paginaFinal" => "S163" "link" => array:1 [ …1] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib38" "etiqueta" => "38." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2008.08548.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2008" "volumen" => "158" "paginaInicial" => "1107" "paginaFinal" => "1116" "link" => array:1 [ …1] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib39" "etiqueta" => "39." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efalizumab in routine use: a clinical experience" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2007.07861.x" "Revista" => array:7 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2007" "volumen" => "156" "numero" => "Suppl 2" "paginaInicial" => "1" "paginaFinal" => "6" "link" => array:1 [ …1] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib40" "etiqueta" => "40." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The effect of weight on the efficacy of biologic therapy in patients with psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2007.11.011" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2008" "volumen" => "58" "paginaInicial" => "443" "paginaFinal" => "446" "link" => array:1 [ …1] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib41" "etiqueta" => "41." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety and efficacy of subcutaneously administered efalizumab in adults with moderate-to-severe hand and foot psoriasis: an openlabel study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Am J Clin Dermatol" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "105" "paginaFinal" => "109" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib42" "etiqueta" => "42." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful treatment of recalcitrant palmoplantar psoriasis with efalizumab" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-3083.2007.02535.x" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2008" "volumen" => "22" "paginaInicial" => "1131" "paginaFinal" => "1134" "link" => array:1 [ …1] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib43" "etiqueta" => "43." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Summary of Product Characteristics for efalizumab <a class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/PDFs/EPAR/raptiva/H-542-PI-es.pdf">http://www.emea.europa.eu/humandocs/PDFs/EPAR/raptiva/H-542-PI-es.pdf</a>" ] ] ] 43 => array:3 [ "identificador" => "bib44" "etiqueta" => "44." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000095037" "Revista" => array:6 [ "tituloSerie" => "Dermatology" "fecha" => "2006" "volumen" => "213" "paginaInicial" => "204" "paginaFinal" => "214" "link" => array:1 [ …1] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib45" "etiqueta" => "45." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clinthera.2005.09.007" "Revista" => array:6 [ "tituloSerie" => "Clin Ther" "fecha" => "2005" "volumen" => "27" "paginaInicial" => "1317" "paginaFinal" => "1328" "link" => array:1 [ …1] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib46" "etiqueta" => "46." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-4632.2006.02777.x" "Revista" => array:6 [ "tituloSerie" => "Int J Dermatol" "fecha" => "2006" "volumen" => "45" "paginaInicial" => "605" "paginaFinal" => "614" "link" => array:1 [ …1] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib47" "etiqueta" => "47." "referencia" => array:1 [ 0 => array:1 [ "host" => array:1 [ 0 => array:1 [ "WWW" => array:1 [ "link" => "http://www.fda.gov/MedWatch/safety/2008/Raptiva_PI.pdf" ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib48" "etiqueta" => "48." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "National Psoriasis Foundation. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2008.03.023" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2008" "volumen" => "59" "paginaInicial" => "209" "paginaFinal" => "217" "link" => array:1 [ …1] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib49" "etiqueta" => "49." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estrategias para optimizar el tratamiento con efalizumab" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2008" "volumen" => "99" "numero" => "Supl 1" "paginaInicial" => "37" "paginaFinal" => "50" "link" => array:1 [ …1] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib50" "etiqueta" => "50." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effective management of a psoriatic flare with narrowband UVB phototherapy during efalizumab therapy without discontinuing treatment" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-3083.2006.01970.x" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2007" "volumen" => "21" "paginaInicial" => "828" "paginaFinal" => "829" "link" => array:1 [ …1] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib51" "etiqueta" => "51." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2007.07766.x" "Revista" => array:7 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2007" "volumen" => "156" "numero" => "Suppl 2" "paginaInicial" => "24" "paginaFinal" => "29" "link" => array:1 [ …1] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib52" "etiqueta" => "52." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2005.10.032" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2006" "volumen" => "54" "paginaInicial" => "S164" "paginaFinal" => "S170" "link" => array:1 [ …1] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib53" "etiqueta" => "53." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Relapse, rebound, and psoriasis adverse events: an advisory group report" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2005.10.029" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2006" "volumen" => "54" "paginaInicial" => "S171" "paginaFinal" => "S181" "link" => array:1 [ …1] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib54" "etiqueta" => "54." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Cutan Med Surg" "fecha" => "2006" "numero" => "Suppl 1" "paginaInicial" => "26" "paginaFinal" => "32" ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib55" "etiqueta" => "55." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.23507" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2008" "volumen" => "58" "paginaInicial" => "1796" "paginaFinal" => "1802" "link" => array:1 [ …1] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib56" "etiqueta" => "56." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efalizumab for the treatment of psoriatic arthritis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Cutan Med Surg" "fecha" => "2007" "volumen" => "11" "paginaInicial" => "57" "paginaFinal" => "66" "link" => array:1 [ …1] ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib57" "etiqueta" => "57." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2008" "volumen" => "35" "paginaInicial" => "883" "paginaFinal" => "890" "link" => array:1 [ …1] ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib58" "etiqueta" => "58." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2230.2006.02315.x" "Revista" => array:6 [ "tituloSerie" => "Clin Exp Dermatol" "fecha" => "2007" "volumen" => "32" "paginaInicial" => "176" "paginaFinal" => "179" "link" => array:1 [ …1] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib59" "etiqueta" => "59." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Clin Dermatol" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "1" "paginaFinal" => "14" "link" => array:1 [ …1] ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib60" "etiqueta" => "60." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2006.02.001" "Revista" => array:6 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "2006" "volumen" => "36" "paginaInicial" => "159" "paginaFinal" => "167" "link" => array:1 [ …1] ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib61" "etiqueta" => "61." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tumor necrosis factor antagonists in the therapy of psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clindermatol.2007.10.030" "Revista" => array:6 [ "tituloSerie" => "Clin Dermatol" "fecha" => "2008" "volumen" => "26" "paginaInicial" => "486" "paginaFinal" => "502" "link" => array:1 [ …1] ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib62" "etiqueta" => "62." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Summary of Product Characteristics for Enbrel <a class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/PDFs/EPAR/Enbrel/H-262-PI-es.pdf">http://www.emea.europa.eu/humandocs/PDFs/EPAR/Enbrel/H-262-PI-es.pdf</a>" ] ] ] 62 => array:3 [ "identificador" => "bib63" "etiqueta" => "63." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized trial of etanercept as monotherapy for psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.139.12.1627" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2003" "volumen" => "139" "paginaInicial" => "1627" "paginaFinal" => "1632" "link" => array:1 [ …1] ] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib64" "etiqueta" => "64." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept as monotherapy in patients with psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa030409" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2003" "volumen" => "349" "paginaInicial" => "2014" "paginaFinal" => "2022" "link" => array:1 [ …1] ] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib65" "etiqueta" => "65." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2005.06688.x" "Revista" => array:7 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2005" "volumen" => "152" "paginaInicial" => "1304" "paginaFinal" => "1312" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib66" "etiqueta" => "66." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2008.08771.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2008" "volumen" => "159" "paginaInicial" => "1177" "paginaFinal" => "1185" "link" => array:1 [ …1] ] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib67" "etiqueta" => "67." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2006.09.002" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2007" "volumen" => "56" "paginaInicial" => "598" "paginaFinal" => "603" "link" => array:1 [ …1] ] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib68" "etiqueta" => "68." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/09546630500472838" "Revista" => array:6 [ "tituloSerie" => "J Dermatolog Treat" "fecha" => "2006" "volumen" => "17" "paginaInicial" => "9" "paginaFinal" => "17" "link" => array:1 [ …1] ] ] ] ] ] ] 68 => array:3 [ "identificador" => "bib69" "etiqueta" => "69." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of Etanercept in an integrated multistudy database of patients with psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2005.11.1088" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2006" "volumen" => "54" "paginaInicial" => "S101" "paginaFinal" => "S111" "link" => array:1 [ …1] ] ] ] ] ] ] 69 => array:3 [ "identificador" => "bib70" "etiqueta" => "70." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.143.6.719" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2007" "volumen" => "143" "paginaInicial" => "719" "paginaFinal" => "726" "link" => array:1 [ …1] ] ] ] ] ] ] 70 => array:3 [ "identificador" => "bib71" "etiqueta" => "71." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sustained long-term clinical efficacy and safety for up to 2.5 years of etanercept in patients with psoriasis. P2908" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2006" "volumen" => "54" "numero" => "3 Suppl" "paginaInicial" => "AB225" ] ] ] ] ] ] 71 => array:3 [ "identificador" => "bib72" "etiqueta" => "72." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of continuous versus intermittent etanercept in patients with moderate to severe psoriasis over 54 weeks: improved efficacy demonstrated in the CRYSTEL Study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "5th EADV Spring Symposium" "conferencia" => "Istanbul, 22-25 May" "serieFecha" => "2008" ] ] ] ] ] ] 72 => array:3 [ "identificador" => "bib73" "etiqueta" => "73." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(00)02530-7" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2000" "volumen" => "356" "paginaInicial" => "385" "paginaFinal" => "390" "link" => array:1 [ …1] ] ] ] ] ] ] 73 => array:3 [ "identificador" => "bib74" "etiqueta" => "74." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with Etanercept" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Clin Exp Rheumatol" "fecha" => "2002" "volumen" => "20" "numero" => "6 Suppl 28" "paginaInicial" => "S116" "paginaFinal" => "S121" "link" => array:1 [ …1] ] ] ] ] ] ] 74 => array:3 [ "identificador" => "bib75" "etiqueta" => "75." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept treatment of psoriatic arthritis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.20335" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2004" "volumen" => "50" "paginaInicial" => "2264" "paginaFinal" => "2272" "link" => array:1 [ …1] ] ] ] ] ] ] 75 => array:3 [ "identificador" => "bib76" "etiqueta" => "76." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with Etanercept" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2006" "volumen" => "33" "paginaInicial" => "712" "paginaFinal" => "721" "link" => array:1 [ …1] ] ] ] ] ] ] 76 => array:3 [ "identificador" => "bib77" "etiqueta" => "77." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept treatment for children and adolescents with plaque psoriasis" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa066886" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2008" "volumen" => "358" "paginaInicial" => "241" "paginaFinal" => "251" "link" => array:1 [ …1] ] ] ] ] ] ] 77 => array:3 [ "identificador" => "bib78" "etiqueta" => "78." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2340/00015555-0511" "Revista" => array:6 [ "tituloSerie" => "Acta Derm Venereol" "fecha" => "2008" "volumen" => "88" "paginaInicial" => "495" "paginaFinal" => "501" "link" => array:1 [ …1] ] ] ] ] ] ] 78 => array:3 [ "identificador" => "bib79" "etiqueta" => "79." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept combined with methotrexate for high-need psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2008.08669.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2008" "volumen" => "159" "paginaInicial" => "460" "paginaFinal" => "463" "link" => array:1 [ …1] ] ] ] ] ] ] 79 => array:3 [ "identificador" => "bib80" "etiqueta" => "80." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Drugs Dermatol" "fecha" => "2008" "volumen" => "7" "paginaInicial" => "245" "paginaFinal" => "253" "link" => array:1 [ …1] ] ] ] ] ] ] 80 => array:3 [ "identificador" => "bib81" "etiqueta" => "81." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2005.10.053" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2006" "volumen" => "54" "paginaInicial" => "S92" "paginaFinal" => "S100" "link" => array:1 [ …1] ] ] ] ] ] ] 81 => array:3 [ "identificador" => "bib82" "etiqueta" => "82." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Information supplied by the manufacturer. Wyeth Pharma." ] ] ] 82 => array:3 [ "identificador" => "bib83" "etiqueta" => "83." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence f rom the Psocare Project" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000156599" "Revista" => array:6 [ "tituloSerie" => "Dermatology" "fecha" => "2008" "volumen" => "217" "paginaInicial" => "365" "paginaFinal" => "373" "link" => array:1 [ …1] ] ] ] ] ] ] 83 => array:3 [ "identificador" => "bib84" "etiqueta" => "84." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-3083.2007.02429.x" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2008" "volumen" => "22" "paginaInicial" => "341" "paginaFinal" => "344" "link" => array:1 [ …1] ] ] ] ] ] ] 84 => array:3 [ "identificador" => "bib85" "etiqueta" => "85." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.phrs.2008.02.006" "Revista" => array:6 [ "tituloSerie" => "Pharmacol Res" "fecha" => "2008" "volumen" => "57" "paginaInicial" => "290" "paginaFinal" => "295" "link" => array:1 [ …1] ] ] ] ] ] ] 85 => array:3 [ "identificador" => "bib86" "etiqueta" => "86." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diverse effects of infliximab and etanercept on T lymphocytes" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2005.01.006" "Revista" => array:7 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "2005" "volumen" => "34" "numero" => "5 Suppl 1" "paginaInicial" => "23" "paginaFinal" => "27" "link" => array:1 [ …1] ] ] ] ] ] ] 86 => array:3 [ "identificador" => "bib87" "etiqueta" => "87." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2005.07078.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2006" "volumen" => "154" "paginaInicial" => "460" "paginaFinal" => "466" "link" => array:1 [ …1] ] ] ] ] ] ] 87 => array:3 [ "identificador" => "bib88" "etiqueta" => "88." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Summary of Product Characteristic for infliximab. <a class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/PDFs/EPAR/Remicade/H-240-PI-es.pdf">http://www.emea.europa.eu/humandocs/PDFs/EPAR/Remicade/H-240-PI-es.pdf</a>." ] ] ] 88 => array:3 [ "identificador" => "bib89" "etiqueta" => "89." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2001" "volumen" => "357" "paginaInicial" => "1842" "paginaFinal" => "1847" "link" => array:1 [ …1] ] ] ] ] ] ] 89 => array:3 [ "identificador" => "bib90" "etiqueta" => "90." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1067/mjd.2003.307" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2003" "volumen" => "48" "paginaInicial" => "829" "paginaFinal" => "835" "link" => array:1 [ …1] ] ] ] ] ] ] 90 => array:3 [ "identificador" => "bib91" "etiqueta" => "91." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2004.02.021" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2004" "volumen" => "51" "paginaInicial" => "534" "paginaFinal" => "542" "link" => array:1 [ …1] ] ] ] ] ] ] 91 => array:3 [ "identificador" => "bib92" "etiqueta" => "92." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(05)67566-6" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2005" "volumen" => "366" "paginaInicial" => "1367" "paginaFinal" => "1374" "link" => array:1 [ …1] ] ] ] ] ] ] 92 => array:3 [ "identificador" => "bib93" "etiqueta" => "93." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2006.11.032" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2007" "volumen" => "56" "paginaInicial" => "31.e1" "paginaFinal" => "31.e15" "link" => array:1 [ …1] ] ] ] ] ] ] 93 => array:3 [ "identificador" => "bib94" "etiqueta" => "94." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000149970" "Revista" => array:6 [ "tituloSerie" => "Dermatology" "fecha" => "2008" "volumen" => "217" "paginaInicial" => "268" "paginaFinal" => "275" "link" => array:1 [ …1] ] ] ] ] ] ] 94 => array:3 [ "identificador" => "bib95" "etiqueta" => "95." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical pharmacokinetics and use of infliximab" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2165/00003088-200746080-00002" "Revista" => array:6 [ "tituloSerie" => "Clin Pharmacokinet" "fecha" => "2007" "volumen" => "46" "paginaInicial" => "645" "paginaFinal" => "660" "link" => array:1 [ …1] ] ] ] ] ] ] 95 => array:3 [ "identificador" => "bib96" "etiqueta" => "96." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Immunopathol Pharmacol" "fecha" => "2007" "volumen" => "20" "paginaInicial" => "647" "paginaFinal" => "650" "link" => array:1 [ …1] ] ] ] ] ] ] 96 => array:3 [ "identificador" => "bib97" "etiqueta" => "97." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Review article: infliximab therapy for inflammatory bowel disease - seven years on" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2036.2006.02786.x" "Revista" => array:6 [ "tituloSerie" => "Aliment Pharmacol Ther" "fecha" => "2006" "volumen" => "23" "paginaInicial" => "451" "paginaFinal" => "463" "link" => array:1 [ …1] ] ] ] ] ] ] 97 => array:3 [ "identificador" => "bib98" "etiqueta" => "98." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2007.07.042" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2008" "volumen" => "58" "paginaInicial" => "224" "paginaFinal" => "231" "link" => array:1 [ …1] ] ] ] ] ] ] 98 => array:3 [ "identificador" => "bib99" "etiqueta" => "99." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Therapies for dactylitis in psoriatic arthritis. A systematic review" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2006" "volumen" => "33" "paginaInicial" => "1439" "paginaFinal" => "1441" "link" => array:1 [ …1] ] ] ] ] ] ] 99 => array:3 [ "identificador" => "bib100" "etiqueta" => "100." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Monoclonal antibodies, immunogenicity, and associated infusion reactions" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Mt Sinai J Med" "fecha" => "2005" "volumen" => "72" "paginaInicial" => "250" "paginaFinal" => "256" "link" => array:1 [ …1] ] ] ] ] ] ] 100 => array:3 [ "identificador" => "bib101" "etiqueta" => "101." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Review and expert opinion on prevention and treatment of infliximab-related infusion reactions" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2008.08728.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2008" "volumen" => "159" "paginaInicial" => "527" "paginaFinal" => "536" "link" => array:1 [ …1] ] ] ] ] ] ] 101 => array:3 [ "identificador" => "bib102" "etiqueta" => "102." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reacciones a la infusión de infliximab en pacientes dermatológicos" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2009" "volumen" => "100" "paginaInicial" => "103" "paginaFinal" => "112" "link" => array:1 [ …1] ] ] ] ] ] ] 102 => array:3 [ "identificador" => "bib103" "etiqueta" => "103." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/429998" "Revista" => array:7 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2005" "volumen" => "41" "numero" => "Suppl 3" "paginaInicial" => "S199" "paginaFinal" => "S203" "link" => array:1 [ …1] ] ] ] ] ] ] 103 => array:3 [ "identificador" => "bib104" "etiqueta" => "104." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.21043" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2005" "volumen" => "52" "paginaInicial" => "1766" "paginaFinal" => "1772" "link" => array:1 [ …1] ] ] ] ] ] ] 104 => array:3 [ "identificador" => "bib105" "etiqueta" => "105." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.22768" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2007" …4 ] ] ] ] ] ] 105 => array:3 [ "identificador" => "bib106" "etiqueta" => "106." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2007.10.011" "Revista" => array:6 [ …6] ] ] ] ] ] 106 => array:3 [ "identificador" => "bib107" "etiqueta" => "107." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Autoimmunity associated with antitumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 107 => array:3 [ "identificador" => "bib108" "etiqueta" => "108." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-TNF therapy in RA and risk of malignant lymphomas. Relative risks and time-trends in the Swedish Biologics Register" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ …2] ] ] ] ] ] 108 => array:3 [ "identificador" => "bib109" "etiqueta" => "109." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jama.295.19.2275" "Revista" => array:6 [ …6] ] ] ] ] ] 109 => array:3 [ "identificador" => "bib110" "etiqueta" => "110." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2004.033993" "Revista" => array:6 [ …6] ] ] ] ] ] 110 => array:3 [ "identificador" => "bib111" "etiqueta" => "111." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical pharmacokinetics of TNF antagonists: how do they differ?" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2005.01.004" "Revista" => array:7 [ …7] ] ] ] ] ] 111 => array:3 [ "identificador" => "bib112" "etiqueta" => "112." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Summary of Product Characteristics for Humira. <a class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/PDFs/EPAR/humira/H-481-PI-es.pdf">http://www.emea.europa.eu/humandocs/PDFs/EPAR/humira/H-481-PI-es.pdf</a>." ] ] ] 112 => array:3 [ "identificador" => "bib113" "etiqueta" => "113." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2007.09.010" "Revista" => array:6 [ …6] ] ] ] ] ] 113 => array:3 [ "identificador" => "bib114" "etiqueta" => "114." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety results from the comparative study of adalimumab (HUMIRA) versus methotrexate versus placebo in psoriasis patients (CHAMPION)" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2007.08315.x" "Revista" => array:6 [ …6] ] ] ] ] ] 114 => array:3 [ "identificador" => "bib115" "etiqueta" => "115." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical response to adalimumab treatment in moderate to severe psoriasis patients: double-blind, randomized clinical trial and open-label extension study" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2006.05.027" "Revista" => array:6 [ …6] ] ] ] ] ] 115 => array:3 [ "identificador" => "bib116" "etiqueta" => "116." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of adalimumab in a 120-week, open-label extension study in patients with moderate to severe chronic plaque psoriasis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 116 => array:3 [ "identificador" => "bib117" "etiqueta" => "117." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "P2654. Psoriasis patients treated continuously with adalimumab: Efficacy and safety results from months 12 to 18" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 117 => array:3 [ "identificador" => "bib118" "etiqueta" => "118." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy outcomes for patients with psoriasis who interrupt adalimumab therapy. Poster FP1384" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ …3] ] ] ] ] ] 118 => array:3 [ "identificador" => "bib119" "etiqueta" => "119." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2007.08.030" "Revista" => array:6 [ …6] ] ] ] ] ] 119 => array:3 [ "identificador" => "bib120" "etiqueta" => "120." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Duration of remission of biologic agents for chronic plaque psoriasis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010000000005/v1_201304241456/S1578219009700861/v1_201304241456/en/main.assets" "Apartado" => array:4 [ "identificador" => "6244" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Consensus statement" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010000000005/v1_201304241456/S1578219009700861/v1_201304241456/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219009700861?idApp=UINPBA000044" ]
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 7 | 108 | 115 |
2024 Octubre | 85 | 55 | 140 |
2024 Septiembre | 91 | 48 | 139 |
2024 Agosto | 114 | 57 | 171 |
2024 Julio | 85 | 38 | 123 |
2024 Junio | 79 | 28 | 107 |
2024 Mayo | 80 | 35 | 115 |
2024 Abril | 78 | 49 | 127 |
2024 Marzo | 87 | 44 | 131 |
2024 Febrero | 70 | 48 | 118 |
2024 Enero | 75 | 53 | 128 |
2023 Diciembre | 86 | 36 | 122 |
2023 Noviembre | 75 | 53 | 128 |
2023 Octubre | 65 | 34 | 99 |
2023 Septiembre | 76 | 48 | 124 |
2023 Agosto | 59 | 21 | 80 |
2023 Julio | 62 | 67 | 129 |
2023 Junio | 63 | 37 | 100 |
2023 Mayo | 71 | 43 | 114 |
2023 Abril | 36 | 38 | 74 |
2023 Marzo | 40 | 43 | 83 |
2023 Febrero | 32 | 33 | 65 |
2023 Enero | 41 | 30 | 71 |
2022 Diciembre | 46 | 39 | 85 |
2022 Noviembre | 16 | 26 | 42 |
2022 Octubre | 19 | 28 | 47 |
2022 Septiembre | 20 | 87 | 107 |
2022 Agosto | 18 | 59 | 77 |
2022 Julio | 16 | 29 | 45 |
2022 Junio | 13 | 33 | 46 |
2022 Mayo | 39 | 62 | 101 |
2022 Abril | 69 | 60 | 129 |
2022 Marzo | 52 | 68 | 120 |
2022 Febrero | 76 | 42 | 118 |
2022 Enero | 79 | 54 | 133 |
2021 Diciembre | 44 | 43 | 87 |
2021 Noviembre | 50 | 51 | 101 |
2021 Octubre | 66 | 52 | 118 |
2021 Septiembre | 78 | 48 | 126 |
2021 Agosto | 55 | 37 | 92 |
2021 Julio | 71 | 48 | 119 |
2021 Junio | 69 | 40 | 109 |
2021 Mayo | 62 | 38 | 100 |
2021 Abril | 134 | 100 | 234 |
2021 Marzo | 104 | 49 | 153 |
2021 Febrero | 56 | 39 | 95 |
2021 Enero | 56 | 21 | 77 |
2020 Diciembre | 60 | 15 | 75 |
2020 Noviembre | 35 | 26 | 61 |
2020 Octubre | 67 | 18 | 85 |
2020 Septiembre | 42 | 20 | 62 |
2020 Agosto | 45 | 27 | 72 |
2020 Julio | 40 | 16 | 56 |
2020 Junio | 43 | 25 | 68 |
2020 Mayo | 40 | 47 | 87 |
2020 Abril | 34 | 33 | 67 |
2020 Marzo | 38 | 22 | 60 |
2020 Febrero | 0 | 5 | 5 |
2020 Enero | 0 | 6 | 6 |
2019 Diciembre | 0 | 5 | 5 |
2019 Octubre | 0 | 5 | 5 |
2019 Septiembre | 0 | 5 | 5 |
2019 Agosto | 1 | 6 | 7 |
2019 Julio | 0 | 2 | 2 |
2019 Junio | 0 | 4 | 4 |
2019 Mayo | 0 | 49 | 49 |
2019 Abril | 0 | 27 | 27 |
2019 Marzo | 0 | 9 | 9 |
2019 Febrero | 1 | 6 | 7 |
2019 Enero | 0 | 4 | 4 |
2018 Junio | 0 | 1 | 1 |
2018 Mayo | 0 | 8 | 8 |
2018 Abril | 0 | 2 | 2 |
2018 Marzo | 3 | 2 | 5 |
2018 Febrero | 36 | 7 | 43 |
2018 Enero | 33 | 9 | 42 |
2017 Diciembre | 29 | 16 | 45 |
2017 Noviembre | 19 | 8 | 27 |
2017 Octubre | 23 | 4 | 27 |
2017 Septiembre | 32 | 20 | 52 |
2017 Agosto | 49 | 11 | 60 |
2017 Julio | 34 | 12 | 46 |
2017 Junio | 35 | 14 | 49 |
2017 Mayo | 37 | 11 | 48 |
2017 Abril | 26 | 26 | 52 |
2017 Marzo | 40 | 5 | 45 |
2017 Febrero | 37 | 12 | 49 |
2017 Enero | 28 | 13 | 41 |
2016 Diciembre | 54 | 13 | 67 |
2016 Noviembre | 26 | 5 | 31 |
2016 Octubre | 35 | 23 | 58 |
2016 Septiembre | 39 | 6 | 45 |
2016 Agosto | 39 | 6 | 45 |
2016 Julio | 38 | 13 | 51 |
2016 Junio | 7 | 13 | 20 |
2016 Mayo | 7 | 13 | 20 |
2016 Abril | 7 | 2 | 9 |
2016 Marzo | 6 | 1 | 7 |
2016 Febrero | 9 | 2 | 11 |
2016 Enero | 6 | 0 | 6 |
2015 Diciembre | 5 | 3 | 8 |
2015 Noviembre | 7 | 0 | 7 |
2015 Octubre | 9 | 2 | 11 |
2015 Septiembre | 5 | 3 | 8 |
2015 Agosto | 11 | 5 | 16 |
2015 Julio | 44 | 7 | 51 |
2015 Junio | 36 | 13 | 49 |
2015 Mayo | 72 | 20 | 92 |
2015 Abril | 61 | 16 | 77 |
2015 Marzo | 33 | 16 | 49 |
2015 Febrero | 28 | 10 | 38 |
2015 Enero | 29 | 13 | 42 |
2014 Diciembre | 39 | 11 | 50 |
2014 Noviembre | 31 | 14 | 45 |
2014 Octubre | 46 | 11 | 57 |
2014 Septiembre | 32 | 15 | 47 |
2014 Agosto | 38 | 18 | 56 |
2014 Julio | 49 | 18 | 67 |
2014 Junio | 34 | 10 | 44 |
2014 Mayo | 44 | 16 | 60 |
2014 Abril | 58 | 16 | 74 |
2014 Marzo | 44 | 13 | 57 |
2014 Febrero | 41 | 23 | 64 |
2014 Enero | 44 | 18 | 62 |
2013 Diciembre | 43 | 14 | 57 |
2013 Noviembre | 29 | 16 | 45 |
2013 Octubre | 30 | 17 | 47 |
2013 Septiembre | 34 | 23 | 57 |
2013 Agosto | 30 | 35 | 65 |
2013 Julio | 40 | 29 | 69 |
2013 Junio | 39 | 29 | 68 |
2013 Mayo | 33 | 15 | 48 |
2013 Abril | 42 | 46 | 88 |
2013 Marzo | 38 | 30 | 68 |
2013 Febrero | 42 | 13 | 55 |
2013 Enero | 10 | 6 | 16 |